The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Interferon-inducible antiviral effectors
Sadler, A. J., & Williams, B. R. G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2314 · Cited by 2,160 · cited 1×
“Secreted type I IFN following TLR7 stimulation results in broad cellular activation and increased transcription of interferon-stimulated genes (ISGs), many of which have antiviral activity [6].”
BackgroundInnate immune recognition of viral infection
Kawai, T., & Akira, S. (2006) · Nature Immunology · doi:10.1038/ni1303 · Cited by 1,899
for the FarmaPEG Study Group, García-García, I., González-Delgado, C. A., Valenzuela-Silva, C. M., Díaz-Machado, A., Cruz-Díaz, M., Nodarse-Cuní, H., Pérez-Pérez, O., Bermúdez-Badell, C. H., Ferrero-Bibilonia, J., et al. (2010) · BMC Pharmacology · doi:10.1186/1471-2210-10-15 · Cited by 33 · cited 1×
“Intra-hepatic IFN-alpha has the potential to protect HBV specific cytotoxic T lymphocytes from NK cell-mediated cytolysis [23,24]; in contrast the exposure to systemic IFN was associated with decline of total cytotoxic T lymphocytes [25].”
Background
Cited by
ISG15 in antiviral immunity and beyond
Perng, Y.-C., & Lenschow, D. J. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0020-5 · Cited by 855
Therapeutic strategies for hepatitis B virus infection: towards a cure
Fanning, G. C., Zoulim, F., Hou, J., & Bertoletti, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0037-0 · Cited by 557
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
Nguyen, M. H., Wong, G., Gane, E., Kao, J.-H., & Dusheiko, G. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-19 · Cited by 554
Self-citationCornberg, M., Lok, A. S.-F., Terrault, N. A., Zoulim, F., Berg, T., Brunetto, M. R., Buchholz, S., Buti, M., Chan, H. L. Y., Chang, K.-M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.003 · Cited by 366
Hepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.008 · Cited by 344
Present and future therapies of hepatitis B: From discovery to cure
Liang, T. J., Block, T. M., McMahon, B. J., Ghany, M. G., Urban, S., Guo, J., Locarnini, S., Zoulim, F., Chang, K., & Lok, A. S. (2015) · Hepatology · doi:10.1002/hep.28025 · Cited by 317
Hepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Hepatology · doi:10.1002/hep.29323 · Cited by 303
HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment
Singh, K. P., Crane, M., Audsley, J., Avihingsanon, A., Sasadeusz, J., & Lewin, S. R. (2017) · AIDS · doi:10.1097/qad.0000000000001574 · Cited by 268
Metadata
- Authors
- Gane, E. J., Lim, Y.-S., Gordon, S. C., Visvanathan, K., Sicard, E., Fedorak, R. N., Roberts, S., Massetto, B., Ye, Z., Pflanz, S., Garrison, K. L., Gaggar, A., Mani Subramanian, G., McHutchison, J. G., Kottilil, S., Freilich, B., Coffin, C. S., Cheng, W., & Kim, Y. J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 63
- Issue
- 2
- Pages
- 320-328
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2002258333
- Cited by
- 190
- References
- 4
- FWCI
- 23.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.